Affymetrix acquired by Thermo Fisher Scientific for $1.3bn; after considering $1.5bn management buy-out offer
Executive Summary
Thermo Fisher Scientific Inc. is paying $14 per share in cash (a 43% premium), or $1.3bn, to acquire public genetic analysis company Affymetrix Inc. (DNA-based systems for research instrumentation and clinical diagnostics). The transaction is expected to close by the end of Q2 2016 and is subject to approval from Affymetrix shareholders (Thermo Fisher board has already approved it). The combined company will feature complementary technologies of both Thermo and Affymetrix in the areas of genomic and cellular analysis.
Deal Industry
- In Vitro Diagnostics
- Pharmaceuticals
- Research, Analytical Equipment & Supplies
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
-
Biotechnology
- Nanotechnology, Chips, etc.
-
Drug Discovery Tools
- Bioinformatics
- Genomics-Proteomics
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Contract
- Intra-Biotech Deal
- Payment Includes Cash
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice